Insider Purchases: Inside the Buy

Tag: Orforglipron

Illustration of a giant Eli Lilly pill capsule spilling cash, rising stock charts, and drug bottles, symbolizing blockbuster earnings, insider buying, and growth momentum.

Elite Buys Ely: Should You Buy Lilly’s Stock Too?

Eli Lilly insiders are opening their wallets after the company crushed Q2 2025 — revenue up 38%, EPS up 92%, and blockbuster drugs Zepbound and Mounjaro fueling a raised guidance. Institutions are all-in, the pipeline is buzzing, but the valuation is sky-high. Is LLY worth chasing at $639, or is patience the better prescription?

Read entire article

Tags: Biopharma, CEO Conviction, CEO insider buying, CEO Stock Purchase, CEOBuyIn, CEOConfidence, Eli Lilly, Eli Lilly vs Novo Nordisk, Funanc1al Insider Series, Funanc1al Stocks to Watch, Funanc1alBiotech, Funanc1alEdge, Funanc1alFun, Funanc1alHumor, Funanc1alInsiderSeries, Funanc1alInsights, Funanc1alInvesting, Funanc1alPharma, Funanc1alStocks, Healthcare Stocks, High Growth Stocks, Insider Buying, Institutional Ownership, LLY, Mounjaro, Obesity Drugs, Orforglipron, Pharmaceutical Earnings, Zepbound